Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Jan 15, 2019 • 2:00 PM EST
Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th
Dec 18, 2018 • 5:00 PM EST
Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance
Dec 17, 2018 • 4:01 PM EST
Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics
Nov 8, 2018 • 9:00am EST
See all events
Nov 7, 2018 • 1:00pm EST
New York, NY
Sep 5, 2018 • 12:30pm EST
St. Regis Hotel, New York, NY
Feb 7, 2019 • 4:30pm EST
Verona Pharma receives WHO approval for “ensifentrine” as recommended INN name for RPL554 https://t.co/BFNSFg4UuM
Retrophin doses first patient in pivotal Phase 3 PROTECT study of Sparsentan for the treatment of IgA nephropathy https://t.co/pk1GGY0LO0
Verona Pharma initiates Phase 2 clinical trial to evaluate dry powder inhaler formulation of RPL554 for maintenance… https://t.co/fRlpHGEMtR